Antibody History, Research Advancements, and Therapeutic Development

Early Discoveries in Antibody Research

The history of antibody research and development dates back to the late 19th century, when the German scientist Emil von Behring. He discovered that antitoxins present in the blood serum from previously infected animals with diphtheria could be used to prevent the disease in another individual.

Since then, the study of antibodies has led to a deeper and more detailed understanding of the immune response and the development of treatments for a wide range of diseases. In the early 1970s, the hybridoma technology was developed, which allowed for the production of monoclonal antibodies (mAbs) – antibodies that are identical and specific to a single antigen. This technology revolutionized the field of antibody research and laid the groundwork for techniques like hybridoma sequencing, which enable precise genetic analysis of monoclonal antibody-producing cells and have further accelerated therapeutic antibody development. 

The Introduction of Monoclonal Antibodies

In the early 1970s, a groundbreaking technique known as hybridoma technology was developed, which allowed for the production of monoclonal antibodies (mAbs) – identical and highly specific antibodies that target a single antigen. This technology revolutionized the field of antibody research and therapeutic applications, allowing for precise targeting of diseases such as cancer, autoimmune disorders, and infectious diseases. Unlike polyclonal antibodies, monoclonal antibodies offer consistent performance and high specificity, making them indispensable in diagnostics, research assays, and clinical treatments.

Monoclonal antibodies have transformed diagnostics and therapeutics, especially in cancer treatment, autoimmune conditions, and infectious diseases. The first FDA-approved monoclonal antibody therapeutics in the 1990s marked a turning point, offering new precision-based therapies. Many of these treatments work by interacting with specific immune cell targets, limiting damage to healthy tissues and improving outcomes.

Recombinant Antibody Technologies

In recent years, the field of recombinant antibody technology has emerged. It enables the development of antibodies through gene-based engineering rather than traditional immunization methods. This approach allows for the production of fully human antibodies in large quantities, with improved batch-to-batch consistency and reduced risk of immunogenicity.

These antibodies are generated by combining a human antibody gene with a host cell, such as Chinese hamster ovary (CHO) cells, to create a recombinant cell line. This synthetic production method also facilitates easier antibody customization, including affinity maturation, subclass switching, and antibody fragment design. Recombinant antibody technology has become a powerful tool in drug discovery and development, allowing for the rapid production of high-quality, fully human antibodies for use in therapeutic applications as well as in preclinical research, diagnostics, and companion diagnostics for personalized medicine.

Biointron's Contribution to Antibody Development

Biointron provides end-to-end recombinant antibody production services that support rapid, scalable, and high-fidelity antibody development from gene synthesis to purified antibody within two weeks. Our state-of-the-art platform enables the rapid expression of a large number of antibodies in CHO cells, with scalable quantities from 100ug to 100g. Suitable for early screening, validation assays, and preclinical studies across a variety of therapeutic areas. We combine advanced vector design, codon optimization, and expression system refinement to ensure optimal antibody performance and stability.

Whether you're developing antibodies for oncology, immunology, infectious disease, or rare disorders, Biointron’s platform enables faster go-to-bench timelines without compromising quality. Learn more about our antibody services and how we support drug discovery pipelines with fast, reliable antibody production.